# RADIAN (NCT05784012)

> Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05784012
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Conditions: Head and Neck Squamous Cell Carcinoma
- Interventions: Dostarlimab; Niraparib; cisplatin plus radiotherapy; Niraparib
- Enrollment: 34
- Primary outcome: 1-year disease free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 3
- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=radian-nct05784012